


**Report: 10/20/2021 Cases: 46**  
**Sites Submitting Patients: 6**

Sociodemographics		
<b>Age: Median (Range)</b>	17.5y (0-39)	
	<b>N</b>	<b>%</b>
<b>Gender</b>		
Female	19	41%
<b>Race / Ethnicity</b>		
Non-Hispanic White	24	57%
Hispanic or Latino	8	20%
Black	7	17%
<b>Insurance</b>		
Public/Uninsured	17	37%
Private	25	54%
<b>Vaccination Location</b>		
Oncology Office	14	30%



Allergic Reaction History		
History of Allergic Reaction	12	29%
To Previous Vaccines	1	2%
To Pegylated Asparaginase	2	4%
To Etoposide	0	0%
Other	10	22%

**Days between Chemotherapy & Vaccine:**  
 Median: 53 days (30-350)

**Previous COVID Infection:**  
 5 (11%)

**Dose #1:** n=44  
**Dose #2:** n=32  
**Dose #3:** n=1

**\*To report cases, find the POCC report, a copy of this report and FAQs, visit:**  
<https://www.uab.edu/medicine/icos/icos-research/the-pocc-report>